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ASSOCIATIONS BETWEEN CARDIAC MANIFESTATIONS OF NOONAN
SYNDROME AND ADVERSE PREGNANCY OURCOMES
Christopher Chow, Katherine Campbell, and Robert Elder.
Yale University School of Medicine, New Haven, CT
The goal of this study was to characterize a population of woman with Noonan syndrome
who had been pregnant in order to determine the safety and feasibility of pregnancy. We
performed a retrospective chart review of patients evaluated at Yale-New Haven Hospital
from 2012-2020 with a diagnosis of Noonan syndrome and pregnancy. We identified 5
women with Noonan syndrome who had a total of 10 pregnancies. In terms of maternal
cardiac disease, 3/5 patients had mild pulmonary valve stenosis at the time of pregnancy,
2 of which had previously undergone interventional cardiac procedures. Out of 10
pregnancies, 5 (50%) resulted in preterm labor (less than 37 weeks gestation). 80% of all
deliveries were converted to Cesarean section after a trial of labor. 1 pregnancy resulted
in intra-uterine fetal demise at 36 weeks while 9 pregnancies resulted in the birth of at
least 1 live infant, for a total of 10 livebirths (due to 1 set of twins). 6/10 (60%) livebirths
required care in the neonatal intensive care unit (NICU). One infant passed away in the
NICU at 5 weeks of age prior to discharge. One pregnancy was complicated by postpartum hemorrhage and 1 pregnancy by a bleeding placenta previa. In conclusion, the
majority of mothers had pre-existing though mild heart disease. Although many of the
pregnancies resulted in living infants, this sample experienced high rates of prematurity,
conversion to Cesarean section, and NICU stays for the neonate, as well as one
occurrence of intrauterine fetal demise and one infant who died in the NICU. Although
some serious maternal complications occurred, none resulted in long-term morbidity.
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INTRODUCTION
Noonan syndrome is a genetic disorder with a constellation of malformations
involving a variety of systems, including distinctive facial features, developmental delay,
renal anomalies, lymphatic malformations, and congenital heart disease [1-3]. The
syndrome was first described by Jacqueline Noonan, a pediatric cardiologist, in a 1963
paper in which she described nine patients with pulmonary valve stenosis, small stature,
hypertelorism, mild intellectual disability, ptosis, undescended testes, and skeletal
malformations [4]. In 1968 she published a case series including these nine patients as
well as an additional ten patients [5]. Since its initial description, the understanding of
Noonan syndrome has expanded greatly to include a broad spectrum of phenotypes, from
seemingly asymptomatic carriers to severe disease. Short stature, distinctive facial
features, and mild cognitive delay are common manifestations, while more significant
morbidity can be caused by coagulation defects, lymphatic malformations, and, most
commonly, congenital heart disease, as discussed below. However, many other organ
systems have been reported to be affected in some proportion of cases, including the
eyes, ears, gastrointestinal system, skeletal system, and genitourinary systems [1]. A 2007
study exploring the long-term natural history of the disease in 112 patients reported a 9%
mortality rate during the 13-year study period, with a mean age at death of 23 years and a
plurality of deaths attributed to cardiac complications of the disease [6]. Similar largescale studies are scarce and there is little data available.
Noonan syndrome is relatively common compared to many other genetic
syndromes, with an estimated prevalence of 1 in 1,000-2,500 live births [1]. However, the
true prevalence is difficult to measure because initiation of a workup for Noonan
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syndrome is typically based on the observation of characteristic clinical features, and thus
many phenotypically mild cases likely go undiagnosed. The advent and increasing
popularity of genetic testing may contribute to more cases being recognized, although
those without a clinically significant phenotype are still less likely to undergo this testing
due to barriers to afforadbility. Although mandatory routine newborn screening for
genetic conditions in the United States currently identifies many cases of metabolic
disorders, immunodeficiencies, and cystic fibrosis, among others, Noonan syndrome is
not currently included on these screens [7]. Whole exome sequencing, the non-targeted
method that sequences the entire protein-coding portion of the genome, may become a
increase diagnoses of Noonan syndrome in the future as technology continues to improve
and costs become less prohibitive [8]. Whole exome sequencing may be particularly
revealing and cost-effective when utilized prenatally when abnormal fetal ultrasound
findings, often present in Noonan syndrome, are detected [9, 10].
Noonan syndrome is either inherited in an autosomal dominant fashion or occurs
sporadically due to a de novo mutation caused by a variety of gene mutations affecting
the RAS-MAPK pathway [11, 12]. This cellular pathway, studied extensively with
regards to its involvement in a variety of oncological processes, is involved in cellular
response to growth factors and results in modulation of cell cycle control, differentiation,
and cell growth. Involvement of this critical pathway places Noonan syndrome within a
larger family of genetic syndromes referred to as “RASopathies,” named for the RASMAPK pathway. This group of syndromes includes neurofibromatosis type 1, Costello
syndrome, LEOPARD syndrome, and cardio-facio-cutaneous syndrome, all of which
have distinctive phenotypes as well as some overlapping features [13]. Advancements in
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genetic testing have demonstrated the genetic heterogeneity of Noonan syndrome and
provided some understanding for the wide spectrum of phenotypes associated with
Noonan syndrome. In 2001, the PTPN11 gene was the first candidate gene to be
identified as causing Noonan syndrome, and is now estimated to be the responsible gene
in approximately 40% of cases [12]. Subsequently, mutations in the genes SOS1, KRAS,
NRAS, RIT1, and RAF1 have been identified as causing large percentages of Noonan
syndrome cases, among many others. While all of these genes can cause Noonan
syndrome, there are certain phenotypic features that are more heavily associated with
specific affected genes. For example, pulmonic stenosis is more often associated with
mutations in SOS1 [14].
While Noonan syndrome affects many organ systems, the cardiac anomalies are
among its more notable manifestations and cause significant mortality and disability
among Noonan patients. Noonan syndrome is the second most common syndromic cause
of congenital heart disease after trisomy 21 [3]. The presence of congenital heart disease
is one of the major factors that led to the original description of the syndrome [4]. The
prevalence of cardiovascular disease among Noonan patients is approximately 80-90%
[15]. The cardiac manifestations of Noonan syndrome can put patients at risk for
arrhythmia, decreased function, or even sudden death, and thus it is important that they
are identified and addressed on an individual basis. Intervention and treatment are
tailored to the structural issue. The cardiac phenotypes most commonly seen in patients
with Noonan syndrome are pulmonary valve stenosis (60-70%), hypertrophic
cardiomyopathy (20-30%), and atrial septal defect (10-30%), with lower prevalence of
atrioventricular canal defect, mitral valve anomalies, coarctation of the aorta, tetralogy of
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Fallot, ventricular septal defect, and aortic root dilatation [16, 17]. The pulmonary valve
stenosis seen in Noonan syndrome is characterized by a dysplastic pulmonary valve with
fibrotic thickening of the annulus and the leaflets, as well as fusion of the valvular cusps
with the wall of the pulmonary artery [16]. This phenotype can put patients at risk for
cardiac remodeling and reduced function, leading eventually to heart failure or arrythmia.
While mild pulmonary valve stenosis does not typically progress in Noonan syndrome
patients, moderate-to-severe stenosis will usually require therapeutic intervention to
prevent progression [18]. Pulmonary valve stenosis is typically treated with balloon
valvuloplasty, notoriously ineffective for the dysplastic pulmonary valve commonly
encountered in Noonan patients, followed by pulmonary valve surgery in refractory cases
[19].
Hypertrophic cardiomyopathy due to Noonan syndrome is often present in early
childhood, and the severity of the condition and high mortality often necessitates
extensive medical and surgical treatment, including but not limited to beta-blockers,
pacemaker placement, and septal myectomy [18]. Cardiac transplantation has been
reported in a handful of severe cases as a potential option for pediatric Noonan syndrome
patients with hypertrophic cardiomyopathy as well [20]. Improved detection and
treatment of congenital heart disease has led to a growing population of adults with
congenital heart disease, with or without an association with a genetic syndrome [21].
As discussed above, there are some loose genotype-phenotype associations
between the abnormal gene and the likelihood of specific cardiac anomalies. Patients
with mutations in the PTPN11 gene are most likely to exhibit pulmonary valve stenosis,
while hypertrophic cardiomyopathy is the dominant cardiac phenotype seen among
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patients with a mutation in RAF1. Meanwhile, nearly all patients (97%) with a RIT1
mutation express cardiac abnormalities, whereas 79% of patients with a PTPN11
mutation had cardiac manifestations in a 2016 study [22].
Advances in genetic technology and increased survival of Noonan syndrome
patients have led to the identification of an increasing population of adults with Noonan
syndrome. Given that survival to adulthood with Noonan syndrome is improving, and
many of the most common forms of congenital heart problems in this population are
manageable in childhood with surgical and transcatheter strategies, women may wish to
become pregnant and start families of their own. Because Noonan syndrome affects
multiple organ systems, it is reasonable to ask how the condition may affect maternal
health, fetal health, and the impact of maternal and fetal Noonan syndrome on the
antepartum, intrapartum, and postpartum course. However, there is a dearth of research
addressing the likelihood of successful pregnancies despite the known medical
complications of the syndrome. Several case studies have collectively described safe
outcomes for nine women with Noonan syndrome who have become pregnant [23-30].
Most notably, a case study published in 1999 described 2 women with Noonan syndrome
who had successful pregnancies despite significant cardiac abnormalities (pulmonary
stenosis and coarctation of the aorta, respectively) [24]. Another study from 2005
describes a single case of a woman with Noonan syndrome who experienced three
pregnancies with fetal demise due to fetal hydrops, likely due to fetal Noonan syndrome,
who was ultimately able to deliver a healthy infant [27]. Interestingly, the majority of
cases published with regards to pregnant Noonan syndrome patients have come from the
field of anesthesiology. Because of the multi-organ system effects of Noonan syndrome,
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multiple case studies have been published in which anesthesiologists had to navigate
challenging pregnancy scenarios including bleeding diathesis, hemodynamic instability,
and difficulty accessing the airway [23, 26, 28-30]. However, no larger studies exist that
explore or compare pregnant patients with Noonan syndrome. Additionally, most of the
existing publications do not take a comprehensive approach to examining both maternal
and fetal health outcomes.
One noteworthy reason for studying pregnant patients with Noonan syndrome is
because of the complex physiological cardiovascular changes which occur during
pregnancy. While systemic vascular resistance decreases throughout pregnancy due to
widespread vasodilation and development of the uteroplacental circulation, cardiac output
increases by as much as 45% by 24 weeks of gestation [31]. Average heart rate also
increases 20-25% by the third trimester, while plasma volume and red blood cell mass
also undergo major increases (30-50% and 50-60%, respectively). Labor itself is
associated with the greatest increase in cardiac output during pregnancy, with increases
of 60-80% compared to levels before onset of labor. Additionally, increased blood
volume can cause an increase in size of all four cardiac chambers, and the gravid uterus
may cause compression of the inferior vena cava or the aorta [32]. All of these
physiologic effects within the cardiovascular system have the potential to exacerbate or
unmask underlying cardiac deficiencies. Inability to meet these demands may result in
arrhythmia, pulmonary edema, or congestive heart failure for the mother, and
uteroplacental insufficiency leading to fetal growth abnormalities or premature delivery
[33]. It is reasonable to explore whether the significant cardiovascular disease present in
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some patients with Noonan syndrome has an effect on their ability to achieve a successful
pregnancy.
The autosomal dominant pattern of inheritance of Noonan syndrome further
complicates the question of pregnancy in Noonan syndrome, as 50% of fetuses can be
expected to inherit and be affected by the maternal gene mutation. Lymphatic
abnormalities can occur in up to 20% of people with Noonan syndrome and contribute to
the likelihood of a successful pregnancy. These abnormalities can range from selfresolving peripheral lymphedema and cystic hygroma to chylous pleural effusions and
hypoplastic lymphatic vessels [34]. In particular, lymphatic abnormalities in a fetus with
Noonan syndrome can pose a danger to its survival, while maternal lymphatics are less
likely to affect the pregnancy. Hydrops fetalis, the accumulation of fluid in at least two
fetal compartments, is a potential life-threatening complication of these lymphatic
abnormalities, and is exacerbated by underlying fetal cardiac dysfunction.
Polyhydramnios may also occur as a result of abnormal lymphatic flow, putting these
fetuses at a higher risk for premature delivery [35].
Fetuses inheriting Noonan syndrome-related mutations may also demonstrate
abnormalities in the placenta during pregnancy, as the placenta is derived primarily from
embryonic cells [36]. Given the wide-ranging and multisystemic manifestations of
Noonan syndrome, it is highly possible that placental manifestations, and therefore
dysfunction, may occur. Such dysfunction in women with Noonan syndrome has not, to
our knowledge, been previously studied, but could be expected to have significant effects
on pregnancy in light of the myriad roles of the placenta and complex maternal-fetal
interactions involved in placental health [37].
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The study of pregnancy in the setting of congenital heart disease has been widely
explored in many conditions other than Noonan syndrome with great benefit, providing
some of the inspiration for this study. A brief literature search for “congenital heart
disease in pregnancy” returns thousands of results studying either specific cardiac
abnormalities or congenital heart disease as a whole. A study of pregnant women with
uncorrected pulmonary valve stenosis found a high rate of serious complications during
pregnancy, delivery, or the neonatal period, including higher than expected rates of
preeclampsia, preterm birth, and offspring mortality [38]. A systemic review of 2,491
pregnancies complicated by congenital heart disease described increased rates of cardiac
complications such as arrythmias and heart failure as compared to the general population,
as well as higher rates of offspring mortality (4% vs 1%) [39]. A study of 90 pregnancies
in 53 women with congenital heart disease demonstrated increased rates of premature
birth, pulmonary edema, and sustained arrhythmias [40]. A recent 2018 systematic
review of pregnant women with Fontan circulation for congenital single ventricle
demonstrated high rates of maternal cardiac complications as well as frequent
miscarriage, intrauterine growth restriction, and premature delivery [41]. A general theme
present throughout many studies is the importance of multidisciplinary counseling,
monitoring, and treatment prior to pregnancy, with obstetricians, cardiologists,
geneticists, and others involved to optimize and prepare patients for a successful
pregnancy. Optimization of cardiovascular health, risk stratification, and anticipation of
complications may greatly influence decision making, including mode of delivery, use of
anesthesia, and even the decision of become pregnant in the first place. The strength of
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this body of literature suggests that it may be useful to explore similar questions in
Noonan syndrome.
We have identified a gap in the literature regarding the question of successful
pregnancy in women with Noonan syndrome. The growing population of adult women
with Noonan syndrome, through increased identification and prolonged survival, is one
factor that has brought this question to light. Advances in the diagnosis and intervention
of congenital heart disease, a common feature of Noonan syndrome, contribute an
additional area of focus to our question: namely, the likelihood of a woman affected by
Noonan syndrome having a successful pregnancy and delivery, and the extent to which
this likelihood is affected by her cardiovascular history and present condition.
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STATEMENT OF PURPOSE
Considering the potential benefit to patients with Noonan syndrome and the
current lack of research in this area, our study was designed to examine a larger sample
of women with Noonan syndrome who have experienced pregnancy in order to further
explore patient characteristics (focusing on cardiac abnormalities) that may contribute to
the likelihood of maternal-fetal complications during pregnancy, delivery, and the
neonatal period.
Hypothesis
The hypothesis of this study is that women with Noonan syndrome who become pregnant
are at greater risk than the general population for the development of maternal-fetal
complications during pregnancy and delivery related to the extent of underlying maternal
cardiac disease.
Specific Aims
Specific Aim 1: This study aims to determine the effect of cardiac health on the
probability of complications during pregnancy and delivery among patients with Noonan
syndrome.
Specific Aim 2: This study aims to determine which interventions, if appropriate, may
limit complications during pregnancy in the case of cardiac disease prior to conception.
Specific Aim 3: This study aims provide data on women with Noonan syndrome who
have become pregnant and given birth in order to understand potential issues in maternalfetal health for this population.
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METHODS
Chart review
We performed a retrospective chart review of patients at a single center, Yale-New
Haven Hospital, from 2012-2020. This time period coincides with the introduction of
electronic medical records at Yale-New Haven Hospital. We utilized the services of the
Yale Joint Data Analytics Team (JDAT) to compile a database including all female
patients in the electronic medical record with a diagnosis of Noonan syndrome in their
medical history who had been evaluated at Yale during that time period for any reason
(29 records.) We reviewed these charts to include only those women who were confirmed
to have either a genetic or unambiguous clinical diagnosis of Noonan syndrome. In order
to be included, patients must have had genetic testing which revealed one of the genetic
mutations commonly associated with Noonan syndrome [11]. Alternatively, we also
included women who had not undergone genetic testing but had a phenotype consistent
with Noonan syndrome as recorded in the medical record by an official genetics
evaluation and a first-degree relative who had undergone genetic testing (in some cases
the offspring of the patient). We then narrowed our study population to those patients
who were recorded as having been pregnant at any time, as determined by a search
through each record for obstetrical notes. We included subjects who were pregnant
outside of the initial time period searched as long as sufficiently detailed records of the
pregnancy were available. We examined these clinical records and extracted information
related to medical history, obstetrical history, and outcomes of the offspring. Medical
history collected included genetic testing, medical conditions, medications, and surgical
history. Obstetrical history obtained included pregnancy course (medications, abnormal
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findings on prenatal screening, pregnancy-related medical conditions), gestational age at
delivery, method of delivery, postpartum course (maternal and fetal), and any genetic
testing performed. We also recorded cardiac conditions and history of intervention to date
for the offspring.
Classification of Pregnancy-Related Complications
Complications were divided into those related to pregnancy, delivery, and
postpartum course. Pregnancy complications included pregnancy-related medical
conditions (preeclampsia, gestational hypertension, gestational diabetes) and abnormal
findings during prenatal screening (ultrasound, chorionic villous sampling,
amniocentesis). Delivery complications included preterm labor (defined as labor prior to
37 weeks gestation), premature rupture of membranes, and conversion to Cesarean
section. Postpartum complications included postpartum hemorrhage (maternal) and
admission to the neonatal intensive care unit (infant).
Echocardiography Image Review
To obtain quantitative cardiac information for patients meeting inclusion criteria,
echocardiography images were analyzed. When possible, the most recent echocardiogram
prior to the first pregnancy was selected for analysis. Alternatively, a recent
echocardiogram performed after the first pregnancy was accepted given the absence of
significant change in cardiac health or function in the intervening time. All raw images
were analyzed by a cardiologist experienced with congenital heart imaging, rather than
by reviewing reports made at the time of the image.
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We graded pulmonary stenosis as mild, moderate, or severe based on the peak
gradient across the valve as measured by Doppler ultrasound. Mild pulmonary stenosis
was defined as a peak gradient less than 36 mmHg, moderate as between 36 and 64
mmHg, and severe as greater than 64 mmHg [42]. Ventricular septal thickening
consistent with hypertrophic cardiomyopathy was suspected if the septum was measured
to be greater than 13 mm thick in any view [43]. Presence or absence of an atrial septal
defect was also specifically evaluated in these images.
Distribution of Labor
All medical record review and data collection were performed by the medical
student. Interpretation of echocardiograms was performed by the thesis advisor with
participation by the medical student. Data analysis and manuscript preparation were
performed by the medical student with review by the thesis advisor.
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RESULTS
We identified 5 women meeting inclusion criteria who had become pregnant a
total of 10 times with 1 twin gestation and a total of 11 fetuses. Nine out of 10
pregnancies occurred within the 9-year period of record review, and 1 pregnancy
occurred prior to that period with sufficient records for review. Because of the paucity of
published cases involving this population, the cases will first be presented individually,
where they may be best understood, before they are analyzed together as a study
population.

Subject 1: 3 pregnancies
The patient has genetically confirmed PTPN1 mutation with a history of pulmonary
stenosis. She has no history of cardiac interventions. Her most recent echo demonstrated
mild pulmonary stenosis and mild aortic insufficiency. She has a remote history of selfresolving ventricular septal defect. Her most recent electrocardiogram (EKG)
demonstrated sinus rhythm with premature ventricular contractions. While she had been
followed by cardiologists for many years prior to becoming pregnant, she did not receive
a formal diagnosis of Noonan syndrome until after her second pregnancy, when her
children underwent genetic testing. Her medical history is also significant for
hypothyroidism.
•

The first pregnancy occurred at maternal age 32 and resulted in a late stillbirth at
36 weeks gestation. Prenatally, the fetus had bilateral pleural effusions and
polyhydramnios. Fetal autopsy showed preductal coarctation of the aorta with
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right ventricular hypertrophy, and a tortuous and congested left descending
coronary artery. Fetal Noonan syndrome was suspected but specific genetic
testing was not performed. The fetus had a normal karyotype and microarray.
•

At age 36, a second pregnancy was complicated by dichorionic-diamniotic twin
gestation, placenta previa hypothyroidism management, and intrauterine
insemination. The twins were delivered at 33 weeks gestation via emergent
Cesarean section due to bleeding secondary to placenta previa. Both infants were
transferred to the neonatal intensive care unit (NICU) for prematurity. The male
infant was diagnosed with Noonan syndrome with pulmonary stenosis, and he
later underwent open surgical repair. The female infant was not found to be
affected by Noonan syndrome.

•

A third pregnancy at maternal age 37 was complicated by anti-K
isoimmunization. Delivery occurred at 37 weeks gestation due to chorion/amnion
separation. The mother was initially induced for trial of labor after Cesarean
section (TOLAC), but transitioned to Cesarean section due to fetal breech
presentation and intrapartum chorioamnionitis. The male infant was delivered
successfully and later diagnosed with Noonan syndrome with moderate
pulmonary stenosis. He underwent balloon dilation of the dysplastic pulmonary
valve followed by surgical pulmonary valvectomy.

Subject 2: 1 pregnancy
The subject has an SOS1 mutation with a cardiac history of pulmonary stenosis. She
underwent surgical repair at 6 months of age. During preconception counseling, she was
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found to have free, severe pulmonary insufficiency related to her prior repair. She
underwent pulmonary valve replacement at 35 years of age, prior to pregnancy. Her
echocardiogram prior to pregnancy was significant for bioprosthetic pulmonary valve
replacement that exhibited mild pulmonary regurgitation and trivial tricuspid
regurgitation with good left ventricular function. EKG showed sinus rhythm. She has no
other significant medical history.
•

Pregnancy occurred at maternal age 36. A prenatal ultrasound at 17 weeks
gestation was significant for bilateral pleural effusions, ascites, membranous
ventricular septal defect, and increased nuchal thickness. The ascites resolved on
subsequent scans. The patient was on metoprolol throughout pregnancy for
palpitations and ventricular ectopy. A female infant was delivered at 39 weeks
gestation by Cesarean section due to failure to progress in the second stage with
meconium-stained fluid. The infant had a short NICU stay for increased work of
breathing requiring continuous positive airway pressure (CPAP). Genetic testing
revealed an SOS1 mutation (R552G) associated with Noonan syndrome. The
infant has been followed for pulmonary stenosis but has not required any
intervention.

Subject 3: 3 pregnancies
The subject was diagnosed with Noonan syndrome at age 11 without genetic testing
due to characteristic facial features and her cardiac history significant for pulmonary
stenosis, which was alleviated at age 12 years via balloon valvuloplasty. A recent echo
demonstrated mild pulmonary stenosis and mild pulmonary insufficiency. Recent EKG
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showed sinus rhythm. Her medical history is otherwise significant for diabetes mellitus
on insulin, chronic anemia, rheumatoid arthritis, and Hashimoto’s thyroiditis. Her
surgical history is significant for multiple esophageal dilation for esophageal webs.
•

The first pregnancy occurred at maternal age 23. A male infant was delivered at
29 weeks gestation by Cesarean section after preterm premature rupture of
membranes (PPROM). The infant stayed in the NICU for 3 months after delivery
due to respiratory distress and growth issues related to prematurity. Genetic
testing revealed PTPN11 with a heterogenous 8228 A-G mutation. The infant was
found to have pulmonary valve stenosis and later underwent balloon
valvuloplasty.

•

A second pregnancy occurred at maternal age 30. The patient received
progesterone injections during pregnancy for history of preterm delivery. Labor
was induced at 33 weeks after PPROM. The male infant was delivered 2.5 days
after induction via repeat Cesarean section for a non-reassuring fetal heart tracing.
The patient reported that the delivery was complicated by postpartum
hemorrhage. The infant was also found to have pulmonary valve stenosis and later
underwent balloon valvuloplasty.

•

Third pregnancy at maternal age 34, complicated by pregestational type 2 diabetes
managed with insulin. This patient again received progesterone injections during
pregnancy due to her history of preterm delivery. The female infant was delivered
via Cesarean section at 32 weeks gestation following PPROM. The infant was
sent to the NICU for hypertrophic cardiomyopathy and severe lymphatic
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abnormalities with chronically draining chylous effusions. In spite of optimal
medical therapy, the infant died at 5 weeks of age.

Subject 4: 2 pregnancies
The subject has confirmed RIT1 mutation without typical cardiac abnormalities.
Recent echo demonstrated mild mitral valve prolapse with mild mitral regurgitation and
patent foramen ovale. Medical history otherwise unremarkable.
•

First pregnancy occurred at maternal age 21. The uncomplicated pregnancy
resulted in normal spontaneous vaginal delivery of a healthy male infant at 39
weeks gestation. There was no known genetic testing and no phenotypic signs of
Noonan syndrome.

•

Second pregnancy at maternal age 23. The pregnancy was complicated by selfresolving cystic hygroma in the fetus. An elective induction of labor at 40 weeks
gestation was complicated by arrest of dilation and subsequent Cesarean section.
Healthy female infant was delivered with uneventful hospital stay. Subsequent
testing has revealed a RIT1 variant of uncertain significance as well as mild
pulmonary stenosis on echocardiogram.

Subject 5: 1 pregnancy
The subject has a confirmed PTPN1 mutation with otherwise unremarkable medical
or cardiac history. Echocardiogram many years after pregnancy was significant for grade
I diastolic dysfunction but not valvular dysfunction.
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•

One pregnancy at maternal age 29. She had an uneventful pregnancy with
delivery at term via Cesarean section for failure to progress. A healthy female
infant was delivered with uneventful hospital course. Genetic testing later
revealed a PTPN1 mutation as an adult. A subsequent echocardiogram did not
demonstrate any abnormality. Medical history significant for mild developmental
delay in childhood.

Summative Results
Out of 5 patients reviewed, 3 carried diagnoses of pulmonary valve stenosis (see
Table 1.) One patient had undergone repair by balloon valvuloplasty and 1 had undergone
open pulmonary valvotomy with closure of an ASD as a child followed by pulmonary
valve replacement as an adult while the third patient had not had any intervention. At the
echocardiogram closest to the time of first pregnancy, all 3 women with pulmonary valve
involvement had mildly elevated peak gradients (range: 15-28 mmHg, mean: 20, SD: 7)
across the pulmonary valve (Figure 1.) 0 out of 5 patients (0%) carried a diagnosis of
hypertrophic cardiomyopathy. 1 out of 5 patients (20%) had a history of atrial septal
defect, repaired at the time of most recent echocardiogram. 1 out of 5 patients (20%) had
no appreciable history of cardiac abnormality. 0 out of 5 patients (0%) had any other
known serious medical comorbidity directly or commonly associated with Noonan
syndrome such as renal disease or bleeding diathesis.
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Figure 1. Representative echocardiography images from Subject 3
A.
A. Color Doppler flow
across pulmonary valve
B. 2D vs color Doppler
comparison across
pulmonary valve
C. Doppler gradient with
B.

velocity measurement
for calculation of degree
of pulmonary stenosis

C.
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Of 10 total pregnancies studied, 9 (90%) resulted in the birth of at least 1 living
infant, while 1 pregnancy (10%) resulted in vaginal delivery of a stillborn infant after
intrauterine fetal demise (see Table 2.) Because 1 delivery was a set of twins, the total
number of living infants delivered was 10. Complications are divided into those affecting
the prenatal course, delivery, and the postpartum period (see Figure 2A.)
Prenatal Course
No maternal patient experienced cardiac or life-threatening complications during
pregnancy. 1 pregnancy resulted in intrauterine fetal demise at 36 weeks with noted
significant lymphatic abnormalities suspicious for fetal Noonan syndrome. 1 pregnancy
was significant for gestational hypertension. 1 pregnancy was significant for a selfresolving cystic hygroma; although this lymphatic abnormality could be indicative of a
fetus affected by Noonan syndrome, it is not considered an adverse prenatal finding. No
cases of pre-eclampsia, gestational diabetes, or other common significant maternal
complications of pregnancy were observed.
Delivery
The average gestational age at delivery among the 10 pregnancies was 36 weeks
(range:29-40 weeks, SD: 3.5 weeks). 5 out of 10 pregnancies (50%) resulted in term
deliveries. 5 out of 10 pregnancies (50%) resulted in preterm labor, with an average
gestational age among preterm deliveries of 33 weeks (range: 29-36 weeks, SD: 2.2
weeks). Of these, 4 out of 5 underwent spontaneous preterm labor, while 1 out of 5
underwent preterm operative delivery for a complication (bleeding placenta previa).
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8 pregnancies (80%) were converted to Cesarean section after a trial of labor for a
variety of reasons including non-reassuring fetal status and failure to progress. Every
Cesarean section resulted in the birth of a living infant. No significant complications
during surgery were apparent.
3 pregnancies (30%) involved maternal complications at the time of delivery – 1
bleeding placenta previa requiring emergent Cesarean section, 1 post-partum
hemorrhage, and 1 case of chorioamnionitis. These events were all resolved without longterm morbidity (see Figure 2B.)
Postpartum
Out of 10 livebirths, 6 infants (60%) required care in the NICU for respiratory
difficulties or prematurity with length-of-stay ranging from 3 days to 3 months. 1 infant
died in the NICU at 5 weeks of age; the remaining infants were able to be discharged
from the hospital. 7 infants out of 11 (64%), including the intrauterine fetal demise,
received the diagnosis of Noonan syndrome after genetic testing; 3 were not felt to have
Noonan syndrome and the 1 infant who had intrauterine fetal demise had highly
suspicious findings for Noonan syndrome but was not formally tested. 5 out of the 6
infants who received NICU care had a diagnosis of Noonan’s syndrome (83%.)
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Table 2. Pregnancy Outcomes

Pregnancy

Pt Age
(years)

1

1

22

2

26

3

27

anti-K
isoimmunization

37

2

1

36

gestational
hypertension

39

3

1

23

none

29

2

30

none

33

3

34

32

1

21

4

Pregnancy
complications

Gestational
Age
(weeks)

Subject
#

intrauterine fetal
demise
dichorionicdiamnionic twin
gestation

pre-gestational
diabetes,
polyhydramnios
none
fetal cystic
hygroma

36
33

39

Delivery

NICU

Noonan
syndrome

NSVD

n/a

unknown

yes/yes

yes/no

no

yes

yes

yes

yes

yes

CS after PPROM, nonreassuring FHR. Postpartum hemorrhage

yes

yes

CS after PPROM

yes

yes

Emergent CS for
bleeding placenta
previa
CS for breech
presentation following
trial of labor,
chorioamnionitis
CS for failure to
progress in 2nd stage,
meconium-stained
fluid
CS after PPROM

NSVD
no
CS after arrest of
2
22
40
no
dilation (eIOL)
CS after failure to
5
1
29 none
term
no
progress
* NSVD = normal spontaneous vaginal delivery, CS = Cesarean section, PPROM = preterm premature
rupture of membranes, eIOL = elective induction of labor, NICU = neonatal intensive care unit

no
unknown
yes
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Figure 2. Pregnancy Complications

A

B

26

DISCUSSION
The study of rare diseases in general is often extremely challenging because of
barriers to subject recruitment and adequate funding [44]. However, findings or even
mere description of these rare diseases can provide valuable guidance for future clinicians
who may have little experience with a specific rare disease, such as Noonan syndrome, in
a high-stakes situation, such as pregnancy. Our study sought to examine the course of
pregnancy and delivery in women with Noonan syndrome in order to determine the risk
of complications depending on maternal cardiac health. We were able to identify a small
population of eligible subjects and demonstrated that successful pregnancy and delivery
were possible for the majority of patients.
One of the accomplishments of this study was the identification and description of
a group of subjects with Noonan syndrome who were able to successfully and safely
become pregnant and deliver. As noted in the introduction, only a small number of case
reports have previously described successful pregnancy in Noonan syndrome, and the
majority of those have focused on specific elements of care, such as complicated
administration of anesthesia [23-30]. Our population is the largest group of these patients
described in a single study. With regards to maternal health, there were no lifethreatening events or complications during the prenatal period. A number of maternal
delivery complications occurred, such as bleeding placenta previa and postpartum
hemorrhage; however, the rates were not noticeably higher than in the greater population
and these patients did not suffer any long-term morbidity. Noticeably, there was a
complete lack of concerning cardiac events, despite the presence of congenital heart
disease in the majority of our sample. In this small sample, having cardiac disease related
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to Noonan syndrome was not associated with maternal health and safety during the
pregnancy and delivery course.
The rates of pregnancy and delivery complications in our study population were
significant, particularly the rates of prematurity, preterm premature rupture of
membranes, conversion to Cesarean section, and need for care in the neonatal intensive
care unit. While the factors contributing to these events are complex and multiple, it is
possible that these high rates may be linked to the underlying Noonan syndrome
diagnosis. The high rates of abnormal findings on intrapartum fetal testing, in some cases
leading to operative delivery by Cesarean section, bring into question the health of the
placenta in maternal-fetal Noonan syndrome. Because many of the infants delivered in
this study were affected by Noonan syndrome, the baseline function of the placenta
(whose genetics are derived from the fetus) may have been compromised. Given the
known deleterious cardiovascular manifestations of Noonan syndrome, it is worth
questioning whether fetal Noonan syndrome could lead to reduced ability of the placenta
to facilitate diffusion of oxygen and nutrients to the fetus, particularly during the stress of
delivery [45]. While the effects of Noonan syndrome have been studied and described in
a wide variety of organ systems, little information exists on placental health, a possible
area of further exploration. The potential for uteroplacental insufficiency in the context of
underlying maternal cardiovascular disease could also contribute to fetal distress and
premature labor. Several subjects had mild pulmonary stenosis on echocardiogram.
However, our data do not support that those with measurable cardiac disease were more
likely to experience complications during pregnancy as compared to those subjects who
had minimal or no cardiac history. That being said, because these echocardiograms were
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not performed during pregnancy, we cannot exclude the possibility that any individual
subject’s cardiac function may have worsened under the strenuous circumstances created
during pregnancy.
The rate of preterm birth prompted by preterm premature rupture of membranes
(PPROM) was unusually high in our population, with 4 total pregnancies resulting in
PPROM. Three of these were observed in a single subject, while the fourth was prompted
by a case of intrauterine fetal demise, making it difficult to generalize this observation to
the Noonan syndrome population. However, this high rate does raise the possibility of the
influence of unknown factors related to Noonan syndrome, in addition to cardiac and
lymphatic abnormalities, that could be contributing to this event. A variety of risk factors
have been described as contributing to the likelihood of PPROM, such as infection,
behavioral factors (e.g., tobacco use), obstetric complications, and genetic predisposition
[46]. These may affect several pathophysiological pathways that may lead to PPROM,
including oxidative stress, excessive collagenolysis, and apoptosis of fetal membranes.
While oxidative stress and buildup reactive oxidative species may be a signal for
initiation of labor in normal pregnancy, PPROM in Noonan syndrome could be an
indicator of unusually high oxidative stress. A link between Noonan syndrome and
collagen dysfunction has not been previously described, although some of the
phenotypical manifestations of Noonan syndrome occur in collagen-rich environments,
such as spinal deformity, synovitis, and disordered lymphangiogenesis, a process which
relies heavily on the extracellular matrix [47]. While these connections are merely
speculative at this time, further study may provide insight both into the pathophysiology
of Noonan syndrome as well as pathophysiological factors influencing PPROM.
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While we cannot directly conclude that worse cardiac function contributed to
pregnancy complications, our study does reinforce the importance for patients with high
risk of cardiac disease to seek multidisciplinary preconception counseling. In fact, one of
the patients in our study (patient 2) presented pre-pregnancy for a cardiac evaluation and
at the time was found to have severe pulmonary insufficiency and significant right
ventricular dilation. She was advised and ultimately went for surgical pulmonary valve
replacement with appropriate recovery and right ventricular remodeling prior to her
pregnancy, which likely resulted in less hemodynamic burden and a better tolerated
pregnancy. This recommendation for pre-conception evaluation is relevant to all women
with Noonan syndrome who wish to become pregnant, particularly if there has been a
prior cardiac history or procedure. Our study population may be selectively biased
towards those patients who had been deemed healthy enough to attempt pregnancy based
on consultation with cardiologists and obstetricians. Several subjects had also undergone
substantial interventional procedures either in childhood or later in life that attempted to
correct previously severe cardiac disease. We can expect that, left uncorrected, severe
cardiac disease would leave patients more vulnerable to complications for the patient and
the fetus. While current recommendations for adults with Noonan syndrome suggest
regular cardiac monitoring, the frequency of such monitoring might reasonably be
increased in the event that a patient wishes to become pregnant.
We observed in our study population that members of the same family
demonstrated significantly different phenotypes despite carrying the same gene mutation.
While not surprising, given our knowledge of Noonan syndrome, we still found the
phenotypic heterogeneity to be striking. For example, several mothers with little to mild
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history of cardiac disease gave birth to infants with significant cardiac disease requiring
early intervention. Similarly, the medical course of siblings with Noonan syndrome was
rarely identical, with some displaying very mild disease and others having Noonan
phenotypes leading to severe and life-threatening neonatal courses. These cases serve as a
reminder of the complexity of inheritance and gene expression, even for a single-gene
autosomal dominant condition. Clinically, affected mothers should be counseled and
monitored closely for every pregnancy, regardless of her own phenotype or the presence
of a previous successful pregnancy. They should be advised explicitly on the meaning of
an autosomal dominant pattern of inheritance, and their attitudes regarding heritability of
a phenotypically diverse syndrome should be explored in depth.
The greatest limitation of our study is the small sample size. While we understood
going into this project that studying a specific subset of a rare disease would make it
difficult to identify a large number of subjects, the eventual number of subjects included
still did not match our expectations of 10-20 subjects based on anecdotal clinical
experience. Some potential subjects could not be included because of a lack of genetic
testing, even if there was strong suspicion that the person likely had Noonan syndrome;
however, due to the already low number of subjects we elected not to include these
subjects in order to avoid diluting any possible conclusions that we might draw. Our
analysis was also restricted to electronic medical records due to their ease of access and
searchability; however, it is possible that more subjects could be located from records
before the widespread use of electronic medical records. The rarity of suitable study
candidates also made it difficult to identify a suitable control group. Ideally, we would be
able to stratify patients based on the extent of their cardiac disease in order to make
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meaningful comparisons between groups. In future studies, it would be beneficial to
expand our population to multiple centers in order to capture a larger study population.
While we did consider this approach for the current study, it unfortunately was not
immediately possible for logistical and administrative reasons.
One effect of our small sample size is that it is more difficult to control for major
factors influencing pregnancy outcomes. For example, one of the pregnancies included in
our study was a twin gestation. Twin gestations are already known to carry higher risk for
certain pregnancy complications, particularly premature labor and PPROM, and thus it is
more difficult to attribute the events of this pregnancy to Noonan syndrome specifically.
As another example, several occurrences of PPROM in our population were attributed to
a single subject, making it difficult to determine whether these events are attributable to
Noonan syndrome, another genetic factor, or an environmental factor. Ideally, in a larger
study, adequate power would enable us to draw more specific conclusions.
Another limitation of our study is its retrospective nature. While we were able to
obtain relevant obstetrical, cardiac, and medical data from reviewing patient charts, this
information is not always complete or as detailed as we may hope. For example, although
we were able to generate quantitative data by directly analyzing patient echocardiograms,
it would have been beneficial to have had additional images from just prior to and
throughout pregnancy as well. Unfortunately, a prospective study capturing many time
points and studies beyond the standard-of-care may be costly and time consuming,
especially considering the difficulty of identifying eligible subjects.
We have succeeded in identifying and describing a small sample of rare patients
with significant health needs. We found that, in our sample, women with Noonan
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syndrome were able to become pregnant and deliver infants, albeit not without
complications among mothers and infants. We hope that this study may contribute to
guidance for future patients and clinicians, as well as act as a foundation for future study
of this condition.
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